The estimated Net Worth of Jonathan T Md Lord is at least $5.9 Million dollars as of 7 December 2022. Jonathan Lord owns over 3,537 units of Biolase Inc stock worth over $2,996 and over the last 21 years he sold BIOL stock worth over $5,643,871. In addition, he makes $249,603 as Independent Chairman of the Board at Biolase Inc.
Jonathan has made over 27 trades of the Biolase Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 3,537 units of BIOL stock worth $2,653 on 7 December 2022.
The largest trade he's ever made was buying 101,163 units of Biolase Inc stock on 3 November 2014 worth over $241,780. On average, Jonathan trades about 9,637 units every 81 days since 2003. As of 7 December 2022 he still owns at least 59,925 units of Biolase Inc stock.
You can see the complete history of Jonathan Lord stock trades at the bottom of the page.
Dr. Jonathan T. Lord M.D. serves as Independent Chairman of the Board of the Company. Dr. Lord is a board-certified forensic pathologist and Fellow of the College of American Pathologists. From March 2012 to January 2013, Dr. Lord was the Chief Operating Officer of the University of Miami Leonard M. Miller School of Medicine and the Uhealth-University of Miami Health System, a healthcare network in south Florida. From August 2011 to March 2012, Dr. Lord served as the Chief Innovation Officer at the University of Miami, Florida. From April 2009 to January 2010, Dr. Lord served as President and Chief Executive Officer of Navigenics, Inc., a privately held healthcare company. Prior to this role, he served as a senior executive in a variety of healthcare organizations including the Anne Arundel Medical Center and SunHealth and served as the Chief Operating Officer of the American Hospital Association. Dr. Lord is also the former Chief Innovation Officer and Senior Vice President of Humana Inc. He began his medical career in the U.S. Navy, serving for 11 years in a number of leadership roles in the Navy Medical Department. From 2008 to 2017, Dr. Lord served on the board of directors of DexCom, Inc., a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems, and from 2010 to 2017, he served as its Chairman. Dr. Lord previously served as a director of Stericycle, Inc., a publicly traded medical and pharmaceutical waste management company, and MAKO Surgical Corp., a publicly traded medical device company that was sold to Stryker Corp. in 2013. Dr. Lord also serves or has served as a director of a number of private companies. Dr. Lord received a Bachelor of Science degree in Chemistry and a Doctor of Medicine degree from the University of Miami. Dr. Lord has also earned certificates in Governance and Audit from Harvard Business School.
As the Independent Chairman of the Board of Biolase Inc, the total compensation of Jonathan Lord at Biolase Inc is $249,603. There are 3 executives at Biolase Inc getting paid more, with Todd Norbe having the highest compensation of $592,590.
Jonathan Lord is 65, he's been the Independent Chairman of the Board of Biolase Inc since 2017. There are 2 older and 10 younger executives at Biolase Inc. The oldest executive at Biolase Inc is Richard R. Whipp, 69, who is the VP of Operations.
Jonathan's mailing address filed with the SEC is 27042 TOWNE CENTRE DR., SUITE 270, FOOTHILL RANCH, CA, 92610.
Over the last 12 years, insiders at Biolase Inc have traded over $9,258,543 worth of Biolase Inc stock and bought 25,366,011 units worth $28,515,794 . The most active insiders traders include Jack W Schuler, Larry Noracle Partners Lp O... und Larry N Feinberg. On average, Biolase Inc executives and independent directors trade stock every 57 days with the average trade being worth of $31,910. The most recent stock trade was executed by Jonathan T Md Lord on 7 December 2022, trading 3,537 units of BIOL stock currently worth $2,653.
biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.
Biolase Inc executives and other stock owners filed with the SEC include: